Clinical Trial Details
| Trial ID: | L7175 |
| Source ID: | NCT04091854 |
| Associated Drug: | Hms5552 |
| Title: | The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Type2 Diabetes Mellitus |
| Interventions: | DRUG: HMS5552 |
| Outcome Measures: | Primary: HbA1c, Changes of HbA1c, 4 weeks|Fasting glucose, Changes of fasting glucose, 4 weeks|Postprandial glucose, Changes of postprandial glucose, 4 weeks|C peptide, Changes of C peptide, 4-8 weeks | Secondary: TNF-α, Changes of TNF-α, 52 weeks|IL-6, Changes of IL-6, 52 weeks|8-iso PGF2α, Changes of 8-iso PGF2α, 52 weeks |
| Sponsor/Collaborators: | Sponsor: Majianhua |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 24 |
| Study Type: | OBSERVATIONAL |
| Study Designs: | Observational Model: |Time Perspective: p |
| Start Date: | 2018-12-12 |
| Completion Date: | 2022-03 |
| Results First Posted: | |
| Last Update Posted: | 2021-08-26 |
| Locations: | Nanjing First hospital, Nanjing, Jiangsu, China |
| URL: | https://clinicaltrials.gov/show/NCT04091854 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|